Compare Amphastar Pharmaceuticals Inc (AMPH) vs AT&T Inc. (T) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs AT&T Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while AT&T Inc. trades at $21.19 (market cap $146.82B). The key difference: AT&T Inc. is far larger — about 177.7× Amphastar Pharmaceuticals Inc's market cap, and AT&T Inc. pays a 5.25% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | T | |
|---|---|---|
Market Cap | $826.08M | $146.82B |
Sector | Health | Media |
52-Week High | $30.81 | $29.62 |
52-Week Low | $16.87 | $20.49 |
Enterprise Value | $1.22B | $292.17B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
AT&T (T) trades at $21.13, up 0.48% today but near 52-week lows, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.11, net income margin of 16.94%, and three consecutive quarterly EPS beats. Recent news highlights SpaceX competition concerns, though the company maintains robust cash flow and a 5.3% dividend yield.
The outlook is mixed: valuation appears attractive with analyst consensus target of $26.43 (25% upside), but technical weakness and competitive threats pose risks. Investment opportunity lies in income generation and potential rebound if execution continues, while key risks include debt levels and industry disruption from new entrants.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
